MAIA Biotechnology, Inc. (MAIA)

-0.08 (-1.58%)
Aug 12, 2022 4:00 PM EDT - Market closed

Company Description

MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer.

THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.

THIO is being developed as a second- or later line of treatment for Non-Small Cell Lung Cancer (NSCLC) for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

THIO will enter Phase 2 human trials in Australia and Europe in the first half of 2022. Based on the clinical data generated by this trial, in late 2024 we plan to seek an accelerated approval of THIO in the United States for the treatment of patients with advanced NSCLC, but even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.

In addition, we plan to start activities for a clinical trial of THIO in patients with advanced colorectal cancer in the first quarter of 2023.

MAIA Biotechnology, Inc.
Country United States
Founded 2018
IPO Date Jul 28, 2022
Industry Biotechnology
Sector Health Care
Employees 9
CEO Vlad Vitoc

Contact Details

444 West Lake Street, Suite 1700
Chicago, IL 60606
United States
Phone 312 416 8592

Stock Details

Ticker Symbol MAIA
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $5.00
CIK Code 1878313
SIC Code 2834

Key Executives

Name Position
Dr. Vlad Vitoc M.B.A., M.D. Co-Founder, President, Chief Executive Officer and Chairman of Directors
Joseph F. McGuire Chief Financial Officer
Dr. Mihail Obrocea M.D. Chief Medical Officer and Head of Development
Dr. Sergei M. Gryaznov Ph.D. Chief Scientific Officer